New hope for rare sarcoma: targeted drug trial opens
NCT ID NCT06942442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called tebentafusp in people with a rare and advanced type of cancer called clear cell sarcoma. Only patients with a specific genetic marker (HLA-A*02:01) can join. The goal is to see if the drug can stop the cancer from growing for at least 24 weeks. About 47 participants will take part in this phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL SARCOMA (CCS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
University of Southern California - Norris Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.